Peer-Reviewed Published Study Shows Advantages of LMA® Gastro™ Airway
WAYNE, Pa.--(BUSINESS WIRE)--Feb. 22, 2018--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices, has announced that newly published research, in the February
2018 edition of the British Journal of Anesthesia, affirms the LMA®
Gastro™ Airway with Cuff Pilot™ Technology yields a high airway
insertion success rate and endoscopy success rate when used in patients
undergoing upper gastrointestinal endoscopy.1
The prospective study, by Nico Terblanche MD, FCA, MMED (Anes) and
colleagues, who are independent from Teleflex, sought to determine the
efficacy of the LMA® Gastro™ Airway in patients undergoing upper
gastrointestinal endoscopy. The study observed 292 patients with ASA
physical status classification 1 or 2, and low risk of pulmonary
aspiration, who received standardized LMA® Gastro™ Airway insertion
during the procedure. The study concluded that the endoscope and LMA®
Gastro™ Airway insertion success was 99%, indicating LMA® Gastro™ Airway
efficacy.1
More than 6.9 million upper endoscopies are performed in the U.S. each
year,2 according to a 2009 study, and the use of
moderate-to-deep sedation during endoscopy is a common practice.
Respiratory depression from sedative drugs and airway obstruction
requiring intervention are known risks associated with these procedures,
with studies demonstrating hypoxemia can occur in 11-50% of cases.3-5
However, today, many of these are undertaken without an airway
management device in place.
The LMA® Gastro™ Airway is the first laryngeal mask specifically
designed to enable clinicians to proactively manage their patients’
airways while facilitating direct endoscopic access via the integrated
channel. With the airway in place, clinicians can easily direct an
endoscope and provide a patent airway for patient safety, which can
facilitate monitoring of end tidal CO2.
“The LMA® Gastro™ Airway was created in response to a true need for a
controlled airway management solution for higher-risk patients
undergoing routine upper GI procedures,” said Justin McMurray, President
and General Manager, Teleflex Anesthesia and Emergency Medicine
Division. “As the market leader in supraglottic airways, Teleflex
continues to develop innovative airway management devices that help
advance clinical practice.”
The peer-reviewed paper appears in the February 2018 issue of the British
Journal of Anaesthesia, which is the oldest and largest independent
journal of anesthesia. The study author was Dr. Terblanche, who works in
the Department of Anaesthesia and Perioperative Medicine at Royal Hobart
Hospital in Tasmania, Australia.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people's lives. We apply
purpose-driven innovation - a relentless pursuit of identifying unmet
clinical needs - to benefit patients and healthcare providers. Our
portfolio is diverse, with solutions in the fields of vascular and
interventional access, surgical, anesthesia, cardiac care, urology,
emergency medicine and respiratory care. Teleflex employees worldwide
are united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rüsch® and Weck® - trusted brands united by a common sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Cuff Pilot, Deknatel, Hudson RCI, LMA, LMA
Gastro, Pilling, Rüsch, and Weck are trademarks or registered trademarks
of Teleflex Incorporated or its affiliates, in the U.S. and/or other
countries.
© 2018 Teleflex Incorporated. All rights reserved. MC-004237
References:
-
Terblanche, NCS, Middleton C. Efficacy of a new dual channel laryngeal
mask airway, the LMA® Gastro™ Airway, for upper gastrointestinal
endoscopy: a prospective observational study. British Journal of
Anesthesia. 2018; 120(2):353-360.
-
Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease
in the United States: 2012 update. Gastroenterology.
2012;143(5):1179-1187 e1171-1173.
-
Qadeer MA, Rocio Lopez A, Dumot JA, Vargo JJ. Risk factors for
hypoxemia during ambulatory gastrointestinal endoscopy in ASA I-II
patients. Dig Dis Sci. 2009;54(5):1035-1040.
-
Cote GA, Hovis RM, Ansstas MA, et al. Incidence of sedation-related
complications with Propofol use during advanced endoscopic procedures. Clin
Gastroenterol Hepatol. 2010;8(2):137-142.
-
de Paulo GA, Martins FP, Macedo EP, Goncalves ME, Mourao CA, Ferrari
AP. Sedation in gastrointestinal endoscopy: a prospective study
comparing nonanesthesiologist-administered Propofol and monitored
anesthesia care. Endosc Int Open. 2015;3(1): E7-E13.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180222005109/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836